HCA Healthcare

Scholarly Commons
Internal Medicine

Research & Publications

1-25-2020

Assessment of Guideline Recommended Anti-Coagulation Rates
for Atrial Fibrillation in an Outpatient Resident Clinic
Kanav Gupta MD
HCA Healthcare, Kanav.Gupta@hcahealthcare.com

Emily Langnas DO
Zahra Khaled
Travis Tagami DO
Alexandra Halalau MD

Follow this and additional works at: https://scholarlycommons.hcahealthcare.com/internal-medicine
Part of the Cardiology Commons, Cardiovascular Diseases Commons, and the Internal Medicine
Commons

Recommended Citation
Gupta K, Langnas E, et al. Assessment of Guideline Recommended Anti-Coagulation Rates for Atrial
Fibrillation in an Oupatient Resident Clinic. Poster presented at: SGIM California-Hawaii Regional Meeting;
January 25, 2020; Irvine, CA.

This Poster is brought to you for free and open access by the Research & Publications at Scholarly Commons. It
has been accepted for inclusion in Internal Medicine by an authorized administrator of Scholarly Commons.

Assessment of Guideline Recommended Anti-Coagulation Rates for Atrial Fibrillation in
an Outpatient Resident Clinic
Kanav Gupta M.D., Emily Langnas D.O., Zahra Khaled M.B.B.S., Travis Tagami D.O., Alexandra Halalau M.D. F.A.C.P.
Oakland University William Beaumont School of Medicine, Rochester, MI; Internal Medicine department, Beaumont Hospital, Royal Oak, MI

Introduction
• Atrial fibrillation is one of the most common arrhythmias with the
propensity to cause a functionally debilitating or fatal stroke.1
• Guidelines recommend using the CHA2DS2-VASc risk score to
calculate a patient’s annual stroke risk. This score is based on a
patient’s past history of and risk factors for cardiovascular
disease. Systemic anticoagulation is recommended for a value
greater than or equal to 2.2
• We hypothesize that physician adherence with the
anticoagulation guidelines in patients with atrial fibrillation is low
in the Beaumont Outpatient Internal Medicine Resident Clinic.

Objectives and Methods
PRIMARY OBJECTIVE: to assess the anticoagulation rates in patients
with atrial fibrillation in the Beaumont Outpatient internal medicine
resident clinic.
SECONDARY OBJECTIVES:
1. Calculate the stroke risk using the CHA2DS2-VASc score to
identify patients
not on anticoagulation in whom it may be indicated.
2. Compare the percentage of patients with atrial fibrillation on
anticoagulation in the Beaumont clinic to the national estimate of
anticoagulation rates for atrial fibrillation.
3. Implement a plan-do-study-act (PDSA) quality improvement (QI)
intervention to improve anticoagulation rates and reduce annual
stroke risk for our clinic patients.
STUDY DESIGN: retrospective cohort and prospective PDSA-QI
intervention.
SETTING: Outpatient internal medicine resident clinic, Beaumont
Hospital, Royal Oak, MI.
PATIENTS: individuals ≥18 years of age who had at least one
encounter in the resident clinic with the diagnosis of atrial
fibrillation who were not on anticoagulation. (See flowsheet)
TIME PERIOD: January 2014-December 2018
CHA2DS2-VASc scores were calculated based on the medical history
and problem list in their electronic medical record (Table 1).

INTERVENTION:
• Investigators sent letters to resident physician primary care
providers informing them that their patient may be eligible for
anticoagulation (CHA2DS2-VASc score ≥2).
• The impact of the intervention was assessed by evaluating if
anticoagulation was prescribed to this population after 6 months.
CHA2DS2-VASc

10,486 patients had a clinic encounter

Score

CHFhistory

1

Hypertension history

1

Age<65

0

Age65-74

1

Age75+

2

Diabetes Mellitus history

1

Stroke/TIA/Thromboembolism history

2

Vascular disease history

1

Sexcategory(Female)

1

Maximum Score

9


688 (6.6%) patients had a diagnosis of atrial
fibrillation


301 (43.8%) patients with atrial fibrillation
were not on anticoagulation

240 (79.7%) patients with atrial fibrillation and
not on anticoagulation had a CHA2DS2-VASc
score of ≥ 2

Results
• The anticoagulation rate in patients with atrial fibrillation is 56.2%
(387 of 688 patients) in the Beaumont resident clinic (Figure 1).
• 240 out of 301 eligible patients, or roughly 79.7%, have a
CHA2DS2-VASc score of 2 or greater and may qualify for
anticoagulation treatment (Figure 2).

301
(43.8%)

387
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61
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94
(31.2%)

Figure 1. Anticoagulation rates in patients
with atrial fibrillation in the resident clinic
Figure 1. Anticoagulation rates in patients
with atrial fibrillation in the resident clinic

146
(48.5%)

• A significant portion (79.7%) of patients in the resident clinic
with a diagnosis of atrial fibrillation who are not on
anticoagulation may qualify for it.
• The rate of anticoagulation in patients with atrial fibrillation
nationwide and at the Beaumont outpatient resident clinic is
suboptimal.3
• Our quality improvement intervention only minimally improved
the rate of anticoagulation in our study population.
STUDY STRENGTHS:
• Study sample included all eligible patients.
• Low risk of ascertainment bias.
STUDY LIMITATIONS:
• The problem list, medical history, and medications of some
patients may not have been updated in their electronic medical
record at the time of data collection.
• Ascertaining the reasoning for why certain patients were
purposely not placed on anticoagulation was not logistically
possible given the constraints of the study.
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Figure 2. CHA2DS2-VASc score in patients not
on anticoagulation in the resident clinic

• The anticoagulation rate in patients with atrial fibrillation at the
Beaumont Outpatient internal medicine clinic is higher than the
national average (56.2% vs. 44.9%) (Figure 3).3
• After the intervention, 12 out of 301 patients who were not on
anticoagulation previously were found to now be on anticoagulation
(Figure 4), 11 of whom had a CHA2DS2-VASc score ≥2.

Figure 4. Effect of intervention on the
number of resident clinic patients with atrial
fibrillation on anticoagulation.
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Figure 3. Comparison of anticoagulation
rates of patients with atrial fibrillation in
the resident clinic versus nationwide.
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